President and Chief Executive Officer
Terry Rich is President and Chief Executive Officer for the Company. Terry has a proven track record of leading global businesses, driving sales execution and building commercial organizations to drive growth. Prior to joining the Company, he led the turnaround of Alphatec Spine from December 2016 through December 2018. As a director and CEO, he strengthened the organization’s competencies, redirected the portfolio with 12 new products and laid the foundation for focused innovation and growth. Prior to Alphatec Spine, Terry was President of Upper Extremities at Wright Medical Group, N.V. Terry has held sales leadership positions at Tornier, NuVasive and DePuy Spine earlier in his career.
Sheryl L. Conley
Chair of the Board of Directors
Ms. Sheryl Conley joined our Board as a director on May 4, 2021, during the Annual Meeting of Stockholders. On September 14, 2021, she was appointed to the role of non-executive Chair of the Board of Directors. Sheryl currently serves as an independent public Board Director for Neuronetics, Inc., and is also a member of its Audit and Nomination and Governance committees (November 2019—present). She is a 35-year veteran of the orthopedic medical device industry with expertise and executive leadership experience in running full P&L business segments, global brand management, marketing, sales, product development, and operations. From September 2012 to May 2017, Sheryl was President and CEO of OrthoWorx, Inc., a community-based initiative that works strategically and collaboratively with the orthopedic industry. Prior to her role as the President and CEO of OrthoWorx, Sheryl spent 25 years with Zimmer, Inc. in a number of escalating management roles across a variety of product segments and geographies, during which she provided key leadership in the development and commercial release of more than 50 industry leading brands, including as Group President, Americas and Global Brand Management, and Chief Marketing Officer from December 2005 until May 2008. She currently serves as the President and Board Member of AcceLINX, Inc., a musculoskeletal health business accelerator (March 2017—present). She also serves as a Board Director of Orthopedics Capital Foundation (2012—present) and since 2019, has been a Board Director for Neuronetics, Inc. a medical technology company focused on developing products that improve the quality of life for patients suffering from psychiatric disorders. Sheryl received a Bachelor of Science in Biology and Chemistry and a Master of Business Administration from Ball State University. Our Board believes that Sheryl’s extensive business acumen in the medical device industry, executive leadership and experience in operations and international markets and her public board experience provides our Board of Directors with valuable expertise in the industry.
Jill Frizzley was appointed to the Company’s board of directors in June 2023. She currently serves as the president of Wildrose Partners LLC, an independent consulting company providing governance and related advisory services to corporations, a position she has held since June 2019. From 2016 through May 2019, she served as Counsel in the Business Finance and Restructuring Group at the law firm of Weil, Gotshal & Manges LLP and before that she began her career at Shearman and Sterling, as an associate in September 2000, and, beginning in January 2010, became a counsel. Ms. Frizzley has served as a director on numerous public and private boards of directors, and currently serves as a director for Virgin Orbit Holdings, Inc., since March 2023 and iMedia Brands, Inc., since April 2023. She previously served on the boards of directors for the following public companies in the last five years: Avaya Holdings Corporation, Hudson Technologies, Inc. and Vivus, Inc. Ms. Frizzley holds a B.Sc. degree from the University of Alberta and an L.L.B. degree from the University of Toronto Faculty of Law.
Elizabeth LaPuma joined the board of directors in June 2023. She has advised on landmark transactions around the globe for over 20 years and in matters totaling trillions of dollars in value. Ms. LaPuma has led UBS's Balance Sheet Advisory Group and ran Alvarez & Marsal Asset Management Services group. She has additionally worked in BlackRock's Financial Advisory Group as well as at Lazard Ltd, the global investment bank, and is currently on the board of Enterra Solutions, a market-leading industrial scale artificial intelligence value chain solutions provider. Ms. LaPuma earned a B.S. in finance and an MBA from the Wharton School, and a B.A. from the School of Arts and Sciences, University of Pennsylvania, graduating summa cum laude and as a Palmer Scholar.
Thomas A. McEachin
Thomas A. McEachin joined the board of directors in December 2015. His executive leadership spans four decades and multiple technology-oriented industries, including medical devices, aerospace, and information systems. Most recently, Thomas was vice president and group chief financial officer of Covidien Surgical Solutions, the largest division of Covidien, plc (now merged into Medtronic). During his tenure at Covidien Surgical Solutions, he transformed the finance team into a high-performance group, providing both strategic counsel and financial discipline to the organization. He helped acquire and integrate several companies as part of a technology diversification strategy. Thomas retired from Covidien in April 2012. Prior to Covidien, Thomas held executive financial positions at United Technologies and its affiliates, Digital Equipment and Xerox. A native New Yorker, Thomas has an M.B.A. from Stanford University’s Graduate School of Business, and a Bachelor of Science in operations research and industrial engineering from New York University’s School of Engineering & Science. He also completed the advanced management program at the Wharton School at the University of Pennsylvania. He is a trustee and officer of the Wadsworth Atheneum, the oldest public art institution in the United States, and serves on their executive, finance, and investment committees. He is also on the board of the Connecticut Science Center, is chair of the audit committee, and a member of the executive and investment committees.
Mark D. Stolper
Mark D. Stolper joined the board of directors in March 2017. Mark has served as executive vice president and chief financial officer of RadNet, Inc., the largest owner and operator of freestanding medical diagnostic imaging centers, since July 2004, and he previously served as a member of the RadNet, Inc. board of directors from March 2004 to July 2004. Mark has diverse experience in investment banking, private equity, venture capital investing and operations, and his background includes roles at Dillon, Read & Co., Inc., Archon Capital Partners, Eastman Kodak, in addition to co-founding Broadstream Capital Partners in 1999. Mark has also served on the board of directors, compensation committee and audit committee of Rotech Healthcare since February 2016. Mark earned a liberal arts degree from the University of Pennsylvania and a finance degree from the Wharton School. Additionally, he earned a postgraduate award in accounting from the University of California, Los Angeles. Mark’s financial background in life sciences, particularly as a current chief financial officer of a publicly-traded company, plus his extensive experience in serving on boards of directors of both public and private companies and his broad mergers and acquisitions experience provides our board of directors with valuable expertise in the industry.
Paul G. Thomas
Paul G. Thomas joined the board of directors in May 2016. Paul most recently served as the chief executive officer of Roka Bioscience, Inc., a molecular diagnostic company, a position he held from 2009 until his retirement in 2017. Paul previously served as chairman, chief executive officer and president of LifeCell Corporation, a publically traded regenerative medicine company from 1998 until it was acquired by KCI in 2008 in a transaction valued at $1.8 billion. Prior to joining LifeCell, he held various senior positions during a 15-year tenure with the pharmaceutical products division of Ohmeda Inc., a world leader in inhalation anesthetics and acute care pharmaceuticals. Paul currently serves on the board of directors of AbioMed (NASDAQ: ABMD). Paul received his bachelor of science in chemistry from St. Michael’s College, his master of business administration from Columbia University, and completed his post graduate studies in chemistry at the University of Georgia. Paul’s extensive leadership experience with companies in the life science industry provides our board of directors with a broad perspective on the industry and valuable management expertise.
Nicholas J. Valeriani
Nicholas J. Valeriani joined the board of directors in May 2016. Nicholas recently retired as the chief executive officer of West Health, The Gary and Mary West Health Institute, an independent nonprofit medical research organization that works to create new and more effective ways of delivering healthcare at lower costs, a position he has held since 2012. Previously, Nicholas served 34 years in key positions at Johnson & Johnson, including company group chairman of Johnson & Johnson Ortho-Clinical Diagnostics; vice president, office of strategy and growth; and as worldwide chairman, medical devices and diagnostics, and corporate vice president, human resources. Nicholas also served on the executive committee of Johnson & Johnson during his tenure. He currently serves on the board of directors of Edwards Lifesciences Corp., and Roka Bioscience, Inc., as well as the Robert Wood Johnson University Hospital. Nicholas received a bachelor’s degree in industrial engineering and a master of business administration from Rutgers University. Nicholas’s background in the global medical device industry and his leadership in the areas of strategy, growth and human resources provides our board of directors with valuable expertise in the industry.